Datasheet: HCA303 BATCH NUMBER 1804

Description:	HUMAN ANTI NIVOLUMAB
Specificity: NIVOLUMAB	
Other names:	Opdivo
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD30264_hlgG1
Isotype:	lgG1
Quantity:	0.1 mg

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .						
	Yes No Not Determined Suggested Dilution						
	ELISA						
	Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.						
Product Form	Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.						
Preparation	Purified IgG prepared by affinity chromatography on Protein A						
Buffer Solution	Phosphate buffered saline						
Preservative Stabilisers	0.01% Thiomersal						
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml						
Immunogen	Nivolumab						
Specificity	Human Anti-Nivolumab Antibody, clone AbD30264_hlgG1 is a paratope specific,						

inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug nivolumab. The antibody does not recognize recombinant human programmed cell death 1 (PD-1) or nivolumab in complex with recombinant human PD-1 and can be used to measure free nivolumab levels in serum from patients.

Clone AbD30264_hlgG1 is a fully human recombinant monoclonal antibody with lgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay.

Nivolumab (Opdivo) is a fully human antibody (IgG4/kappa), with the heavy chain mutation S228P (IgG4-Pro). It is used as a first line treatment for inoperable or metastatic melanoma in combination with ipilimumab if the cancer does not have a mutation in BRAF. It is also approved for treatment of advanced non-small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin's lymphoma and advanced head and neck squamous cell carcinoma. Nivolumab is a checkpoint inhibitor and acts as an immuno-modulator by blocking ligand activation of PD-1 receptor on T cells, thereby activating T cells to attack the cancer. Nivolumab blocks PD-1 interaction with PD-1 ligand (PD-L1) and PD-1 ligand 2 (PD-L2).

View a summary of all anti-nivolumab antibodies

Affinity	The monovalent intrinsic affinity of AbD30264_hIgG1 was measured as K_D = 14 nM by real time, label free molecular interaction analysis on immobilized nivolumab			
ELISA	Clone AbD30264_hlgG1 can be used in a direct or indirect ELISA. Furthermore, it may be used as a calibrator for the set-up of an anti-drug antibody assay.			
	Protocol: Anti-drug antibody assay			
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.			
Guarantee	12 months from date of despatch			
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Opdivo is a trademark of Bristol-Myers Squibb Company.			
Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA303 10094			
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.			

Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>

Related Products

Recommended Negative Controls

RECOMBINANT HUMAN IgG1 LAMBDA ALLOTYPE G1m3 (HCA049)

Recommended Useful Reagents

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P) HISPEC ASSAY DILUENT (BUF049A) MOUSE ANTI HUMAN IgG (Fc) CH2 DOMAIN:HRP (MCA647P)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europ
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739	
	Email: antibody_sales_us@bio-rad.com		Email: antibody_sales_uk@bio-rad.com	

Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M371746:200612'

Europe

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint